We submitted 229 tissue samples of 90 patients with prostatic hyperplasia and 51 patients with prostatic cancer to flow-cytometry DNA analysis. Samples were obtained with different modalities. Needle biopsy proves an effective method to provide adequate tissue samples. Results show that more than one sample is necessary in order to establish the cytometric pattern of hyperplastic and neoplastic prostate glands. Both aneuploidy and high S-phase can be found in BPH. Prostatic cancer is often heterogeneous at DNA analysis; aneuploidy can be found more frequently than in hyperplastic tissue and can be of different type.
McNealJ.E.KindrachukR.A.FreihaF.S.BostwickD.G.RedwineE.A.StameyT.A.: Patterns of progression in prostate cancer. Lancet11: 60–63, 1986.
2.
DeitchA.D.de Vere WhiteR.: Flow cytometry as a predictive modality in prostate cancer. Human Pathol., 23, 4: 352–359, 1992.
3.
AdolfssonJ.RonstromL.HedlundP.O.LowaghenT.CarstensenJ.TribukaitB.: The prognostic value of modal deoxyribonucleic acid in Low Grade, Low Stage untreated Prostate Cancer. J. Urol., 144: 1404–1407, 1990.
4.
DejeterS.W.CunninghamR.E.NoguchiP.D.JonesR.V.MoullJ.W.McLeodD.G.LynchJ.H.: Prognostic significance of DNA ploidy in carcinoma of prostate. Urology 33, 5: 361–366, 1989.
5.
PetersenS.E.: Accuracy and reliability of flow cytometry DNA analysis a simple, one-step ethidium-bromide staining protocol. Cytometry7: 301, 1986.
6.
KallioniemiO.P.VisakorpiT.HolliK.HeikkinenA.IsolaJ.KoivulaT.: Improved prognostic impact of S-Phase values from paraffin. Embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry, 12: 413–421, 1991.
7.
DeitchA.D.StrandM.A.deVere WhiteR.W.: Deoxyribonucleic acid flow cytometry of benign prostatic discase. J. Urol., 142: 759–762, 1989.
8.
EskelinenM.LipponenP.MajapuroR.SyrjanenK.NordlingS.: DNA ploidy, S phase fraction and G2 fraction as prognostic determinants in prostatic adenocarcinoma. Eur. Urol., 20: 62–66, 1991.
9.
VisakorpiT.: Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry As a prognostic factor in prostatic carcinoma. J. Pathol., 168: 7–13, 1992.
10.
PianonR.CurriP.SchiavoneD.D'AmicoA.BeltramiP.AzzolinaL.S.FranzolinN.BianchiG.MobilioG.: Recenti progressi per una più accurata analisi FCM del DNA nell'iperplasia prostatica benigna. Acta Urol. Ital., 4: 391–392, 1992.
